| Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. | |
| | |
MedLine Citation:
|
PMID: 11002955 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess the safety and efficacy of enoxaparin use for thromboprophylaxis or treatment of venous thromboembolism during pregnancy. DESIGN: Retrospective review of casenotes of women who received enoxaparin during pregnancy. SETTING: Obstetric Medicine Unit at Glasgow Royal Maternity Hospital. SAMPLE: Data were obtained on 57 pregnancies in 50 women over six years. METHODS: Information was obtained from case records in relation to outcome measures, the presence of underlying thrombophilia and indication for anticoagulation. MAIN OUTCOME MEASURES: Incidences of venous thromboembolism, haemorrhage, thrombocytopenia, peak plasma anti-factor Xa levels and symptomatic osteoporosis. RESULTS: There were no thromboembolic events in the thromboprophylaxis group. There were no incidences of heparin-induced thrombocytopenia. Twenty-two women had spinal or epidural anaesthesia and no complications were encountered. There was one instance of antepartum haemorrhage following attempted amniotomy in a woman with previously unknown vasa praevia. Two women sustained postpartum haemorrhage, both secondary to vaginal lacerations, resulting in blood loss > 1,000 mL. Blood loss following caesarean section was not excessive. No instances of vertebral or hip fracture were encountered. The median peak plasma anti-factor Xa level on a dose of 40 mg once daily was 0.235 U/mL; peak plasma anti-factor Xa levels were not affected by gestational age. CONCLUSIONS: The use of enoxaparin in pregnancy is associated with a low incidence of complications and a dose of 40 mg once daily throughout pregnancy provides satisfactory anti-factor Xa levels and appears effective in preventing venous thromboembolism. |
| | |
Authors:
|
J Ellison; I D Walker; I A Greer |
Related Documents
:
|
3728605 - The relationship between capillary and venous glucose concentration during pregnancy. 8967705 - Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient... 21766175 - Perinatal mortality and morbidity in twin pregnancies: the relation between chorionicit... 21984575 - Do assisted conception twins have an increased risk for anencephaly? 9029385 - Cord blood carbohydrate-deficient transferrin levels are markedly higher than maternal. 10464615 - A simple vntr-pcr method for detecting maternal cell contamination in prenatal diagnosis. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: BJOG : an international journal of obstetrics and gynaecology Volume: 107 ISSN: 1470-0328 ISO Abbreviation: BJOG Publication Date: 2000 Sep |
Date Detail:
|
Created Date: 2000-10-12 Completed Date: 2000-10-12 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 100935741 Medline TA: BJOG Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 1116-21 Citation Subset: AIM; IM |
Affiliation:
|
University Department of Obstetrics and Gynaecology, Glasgow Royal Maternity Hospital and Glasgow Royal Infirmary, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anticoagulants / therapeutic use* Enoxaparin / therapeutic use* Factor Xa / metabolism Female Gestational Age Humans Pregnancy Pregnancy Complications, Cardiovascular / drug therapy*, prevention & control Prenatal Care / methods Retrospective Studies Thromboembolism / drug therapy*, prevention & control Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Enoxaparin; EC 3.4.21.6/Factor Xa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of ...
Next Document: A discrepancy between gestational age estimated by last menstrual period and biparietal diameter may...